A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
Status:
RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.
Phase:
PHASE3
Details
Lead Sponsor:
Fundación para la Investigación del Hospital Clínico de Valencia